IP Library Granted Patent US 10,071,088
Granted Patent B2
US 10,071,088 · App. 13/918,143 · Granted Sep 11, 2018

Anti-nausea drug combinations

Inventor: C. Andrew Fleming (Indianapolis, IN)
A61K31/485A61K31/167A61K31/198A61K31/27A61K31/405A61K31/465
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,071,088
App. No.
13/918,143
Granted
Sep 11, 2018
Kind
B2
Abstract

Methods and compositions are disclosed for reducing Post Operative Nausea and/or Vomiting (PONV) in a human patient in need of general anesthesia. Such methods may include scheduling surgery for the human patient and administering to the patient one or more series of prescribed medicines days during a regimen preceding general anesthesia to condition receptors involved in the nausea and/or vomiting reflex.

Claims (9)

1. A method for reducing post-operative nausea or vomiting in a human patient in need of general anesthesia for surgery, comprising the acts of:

scheduling surgery for the human patient to occur on a future surgery date, said scheduled surgery to include general anesthesia;

administering to the patient one or more series of prescribed medicines during a conditioning phase preceding said general anesthesia;

wherein said one or more series of prescribed medicines includes a dose of a first prescribed medicine selected from the group consisting of serotonergic agonists, selective serotonin reuptake inhibitors, nicotinic acetylcholine receptor agonists, muscarinic receptor agonists, and dopaminergic agonists;

wherein said one or more series of prescribed medicines includes a dose of a second prescribed medicine selected from the group consisting of opioids and analgesics during said conditioning phase;

wherein the act of said administering includes administering dosages of:

(a) 5-hydroxytryptophan, daily, 50 milligrams per day for four days, then 100 milligrams per day for four days, then 150 milligrams per day for four days, then 200 milligrams per day for two days;

(b) levodopa, daily, 50 milligrams per day for four days, then 100 milligrams per day for four days, then 150 milligrams per day for four days, then 200 milligrams per day for two days;

(c) hydrocodone, daily, 2.5 milligrams per day for eight days, then 5 milligrams per day for six days.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 15, 2016
From: FLEMING, C. ANDREW
To: PRECONDIT, LLC
Reel/Frame 037977/0479 →
Continuity (2)
Provisional Application 61664622 · Jun 26, 2012
Related Publication 20130345250A1 · Dec 26, 2013